BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-...
Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpoint Company to host investor conference call and webcast on ASCO clinical updates on Friday, May 29 at 8:00 p.m. ET CAMBRIDGE, Mass. and BEIJING, China, May …